Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Journey Medical Corporation (DERM) vs Organigram Global Inc. (OGI)

Journey Medical Corporation and Organigram Global Inc. are both Drug Manufacturers Specialty & Generic companies. Journey Medical Corporation is the larger, with a market value of $178.4M against $155.1M — 1.2× the size. Journey Medical Corporation has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.4×. Organigram Global Inc. grew revenue faster over the last twelve months: 39.5% against 20.9%. Organigram Global Inc. has the higher net margin (28.4% vs −8.95%) and the higher return on invested capital (−1.53% vs −5.89%). Across the 19 metrics below, Organigram Global Inc. leads on 17 and Journey Medical Corporation on 2.

Valuation

Metric DERM OGI Drug Manufacturers Specialty & Generic median
P/E n/m 2.37 20.14
P/S 2.48 0.67 2.25
P/B 5.26 0.42 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA 96.75 16.79 12.29
EV/Sales 2.47 0.70 2.56
Earnings yield (3.58%) 42.26% (2.99%)
Free cash flow yield (13.32%) (14.22%) 0.00%

Profitability

Metric DERM OGI Drug Manufacturers Specialty & Generic median
Gross margin 65.45% 36.47% 53.94%
Operating margin (4.41%) (3.91%) 0.00%
Net margin (8.95%) 28.44% 0.00%
Free cash flow margin (10.99%) (9.46%) 0.00%
Return on equity (23.77%) 20.20% (0.40%)
Return on assets (6.80%) 12.70% (3.32%)
Return on invested capital (5.89%) (1.53%) 0.00%

Growth

Metric DERM OGI Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 20.89% 39.51% 10.01%
EPS growth (last fiscal year) 34.72% 60.00% —
Revenue growth, 5-year CAGR 6.79% 24.30% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DERM OGI Drug Manufacturers Specialty & Generic median
Debt to equity 0.79 0.04 0.05
Current ratio 1.59 2.61 2.31
Net debt to EBITDA (0.35) (31.56) 0.85

Dividend

Metric DERM OGI Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric DERM OGI Drug Manufacturers Specialty & Generic median
Market cap 178.38m 155.11m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack